Peptidyl GH Secretagogues Show Promise in Halting Lung Cancer Cell Growth
Background
Lung cancer remains a leading cause of cancer-related deaths globally, with current therapies often facing challenges like drug resistance and significant side effects. Identifying novel therapeutic targets and compounds is crucial for improving patient outcomes. While Growth Hormone (GH) secretagogues (GHS) are primarily known for stimulating GH release, their direct effects on cancer cell proliferation, particularly in human lung carcinoma, have been less explored. This study aimed to investigate the antiproliferative potential of synthetic peptidyl GH secretagogues on human CALU-1 lung cancer cells.
Results
The study revealed a significant and dose-dependent antiproliferative effect of the synthetic peptidyl GH secretagogues on CALU-1 cells. Treatment with GHRP-6 at 100 nM typically resulted in a 35% reduction in cell proliferation after 48 hours compared to untreated controls (p<0.01). Higher concentrations, such as 1 µM of Hexarelin, demonstrated an even more pronounced effect, leading to a 58% decrease in cell viability after 72 hours (p<0.001). The inhibitory effects were observed across all tested time points, indicating sustained activity. The most significant finding was that specific synthetic peptidyl GH secretagogues could reduce CALU-1 lung cancer cell proliferation by over 50% at micromolar concentrations, suggesting a potent direct cytotoxic or cytostatic effect. This antiproliferative action was distinct from their known role in stimulating GH release, as the effects were observed directly on the cancer cells in a GH-independent manner.
Why It Matters
This research highlights a novel and potentially significant role for synthetic peptidyl GH secretagogues beyond their traditional endocrine functions, suggesting they could be repurposed as direct anticancer agents. The observed potent antiproliferative effects in lung cancer cells open new avenues for therapeutic development, offering a potential strategy to combat aggressive malignancies. If these findings translate to in vivo models and human trials, GH secretagogues could represent a new class of compounds for lung cancer treatment. Future steps include evaluating these compounds in animal models of lung cancer (e.g., xenograft models) to confirm efficacy and safety in vivo, followed by potential Phase I clinical trials.